Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - grepid
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp744dd2d849c3e92fc852e3f500b2711e
identifier: http://ema.europa.eu/identifier
/EU/1/09/535/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Grepid 75 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-744dd2d849c3e92fc852e3f500b2711e
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/09/535/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - grepid
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Grepid contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. Platelets are very small structures in the blood which clump together during blood clotting. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).
Grepid is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack or death).
You have been prescribed Grepid to help prevent blood clots and reduce the risk of these severe events because:
Do not take Grepid
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Grepid.
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Grepid:
if you have had a clot in an artery of your brain (ischemic stroke) which occurred within the last seven days.
if you have kidney or liver disease.
if you have had an allergy or reaction to any medicine used to treat your disease.
if you had a past medical history of non-traumatic brain hemorrhage.
While you are taking Grepid:
Children and adolescents Do not give this medicine to children because it does not work.
Other medicines and Grepid Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Some other medicines may influence the use of Grepid or vice versa.
You should specially tell your doctor if you take:
If you have experienced severe chest pain (unstable angina or heart attack), transient ischemic attack or ischemic stroke in mild severity, you may be prescribed Grepid in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. An occasional use of acetylsalicylic acid (not more than 1 000 mg in 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Grepid with food and drink Grepid may be taken with or without food.
Pregnancy and breast-feeding It is preferable not to take this medicine during pregnancy.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or pharmacist before taking Grepid. If you become pregnant while taking Grepid, consult your doctor immediately as it is recommended not to take Grepid while you are pregnant.
You should not breast-feed while taking this medicine. If you are breast-feeding or planning to breast-feed, talk to your doctor before taking this medicine.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines Grepid is unlikely to affect your ability to drive or to use machines.
Grepid contains lactose If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.
Grepid contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose, including for patients with a condition called atrial fibrillation (an irregular heartbeat), is one 75 mg tablet of Grepid per day to be taken orally with or without food, and at the same time each day.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg or 600 mg of Grepid (4 or 8 tablets of 75 mg) once at the start of treatment. Then, the recommended dose is one 75 mg tablet of Grepid per day as described above.
If you have experienced symptoms of a stroke which go away within a short period of time (also known as transient ischemic attack) or an ischemic stroke mild in severity, your doctor may give you 300 mg of Grepid (4 tablets of 75 mg) once at the start of treatment. Then, the recommended dose is one 75 mg tablet of Grepid per day as described above with acetylsalicylic acid for 3 weeks. Then the physician would prescribe either Grepid alone or acetylsalicylic acid alone.
You should take Grepid for as long as your doctor continues to prescribe it.
If you take more Grepid than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
If you forget to take Grepid If you forget to take a dose of Grepid, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
If you forget for more than 12 hours, simply take the next single dose at the usual time. Do not take a double dose to make up for a forgotten tablet.
If you stop taking Grepid Do not stop the treatment unless your doctor tells you so. Contact your doctor or pharmacist before stopping.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediately if you experience:
The most common side effect reported with Grepid is bleeding. Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in the urine. In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.
If you experience prolonged bleeding when taking Grepid If you cut or injure yourself, it may take longer than usual for bleeding to stop. This is linked to the way your medicine works as it prevents the ability of blood clots to form. For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern. However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 Warnings and precautions ).
Other side effects include:
Common side effects (may affect up to 1 in 10 people):
Diarrhoea, abdominal pain, indigestion or heartburn.
Uncommon side effects (may affect up to 1 in 100 people): Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness.
Rare side effects (may affect up to 1 in 1 000 people):
Vertigo, enlarged breasts in males.
Very rare side effects (may affect up to 1 in 10 000 people):
Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of food.
Side effects with frequency not known (frequency cannot be estimated from the available data): Hypersensitivity reactions with chest or abdominal pain, persistent low blood sugar symptoms.
In addition, your doctor may identify changes in your blood or urine test results.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and on the blister, after EXP. The expiry date refers to the last day of that month.
Store below 25 C.
Do not use this medicine if you notice any visible sign of deterioration.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Grepid contains
What Grepid looks like and contents of the pack
Grepid film-coated tablets are pink, round and biconvex.
They are supplied in PVC/PE/PVDC/Alu blisters packed in cartons containing 10, 14, 28, 30, 50, 84, 90 or 100 film-coated tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Greece
Manufacturers Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Greece Or Pharmathen International S.A Industrial Park Sapes,
Rodopi Prefecture, Block No 5,
Rodopi 69300,
Greece or Orifarm Generics A/S Energivej 5260 Odense S,
Denmark
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Pharmathen S.A. T l/Tel: +30 210 66 04 Lietuva SIA ELVIM Tel: +371 67808
Pharmathen S.A. Te .: +30 210 66 04 Luxembourg/Luxemburg Pharmathen S.A. Tel: +30 210 66 04 esk republika Pharmathen S.A. Puh/Tel: +30 210 66 04 Magyarorsz g
Pharmathen S.A. Tel.: +30 210 66 04 Danmark Orifarm Generics A/S Tlf: +45 63 95 27 Malta Pharmathen S.A. Tel: +30 210 66 04 Deutschland Pharmathen S.A. Tel: +30 210 66 04 Nederland Glenmark Pharmaceuticals B.V. Tel: +31 (0)8003355Eesti (Estonia) Pharmathen S.A. Tel: +30 210 66 04 Norge Orifarm Generics AS Tlf: + 47 21 69 69
INNOVIS PHARMA
: +30 210 6664805- sterreich
Pharmathen S.A. Tel: +30 210 66 04 Espa a Pharmathen S.A. Tel: +30 210 66 04 Polska Symphar Sp. z o.o. Tel.: +48 22 822 93 France Pharmathen S.A. T l: +30 210 66 04 Portugal Pharmathen S.A. Tel: +30 210 66 04 Hrvatska Pharmathen S.A. Tel: +30 210 66 04 Rom nia Neola Pharma SRL Tel: +40-(0)21-233 17 Ireland Pinewood Healthcare Tel: + 353 52 6186Slovenija Pharmathen S.A. Tel: +30 210 66 04 sland Alvogen ehf. S mi: +354 522 2Slovensk republika
Valeant Slovakia s.r.o.
Tel: + 421 2 6920 3Italia Pharmathen S.A. Tel:+30 210 66 04 Suomi/Finland Ailon Pharma Oy
Puh/Tel: +358 40 702 4
The Star Medicines Importers Co. Ltd
: +357 25371Sverige
Orifarm Generics AB Tel: +46 40 680 02 Latvija
SIA ELVIM Tel: +371 67808United Kingdom (Northern Ireland) Athlone Pharmaceuticals Tel: +44 (0) 845 4375This leaflet was last revised in Month YYYY.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/
Entry 1 - fullUrl = Composition/composition-en-744dd2d849c3e92fc852e3f500b2711e
Resource Composition:
Generated Narrative: Composition composition-en-744dd2d849c3e92fc852e3f500b2711e
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/09/535/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - grepid
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp744dd2d849c3e92fc852e3f500b2711e
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp744dd2d849c3e92fc852e3f500b2711e
identifier:
http://ema.europa.eu/identifier
/EU/1/09/535/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Grepid 75 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en